BMY Straddle Strategy
BMY (Bristol-Myers Squibb Company), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis.
BMY (Bristol-Myers Squibb Company) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $130.12B, a trailing P/E of 14.01, a beta of 0.23 versus the broader market, a 52-week range of 42.52-68.1, average daily share volume of 11.7M, a public-listing history dating back to 1972, approximately 33K full-time employees. These structural characteristics shape how BMY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.23 indicates BMY has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. BMY pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a straddle on BMY?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
BMY snapshot
As of August 14, 2026, spot at $63.97, ATM IV 24.73%, IV rank 20.20%, expected move 7.09%. The straddle on BMY below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this straddle structure on BMY specifically: BMY IV at 24.73% is on the cheap side of its 1-year range, which favors premium-buying structures like a BMY straddle, with a market-implied 1-standard-deviation move of approximately 7.09% (roughly $4.54 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BMY expiries trade a higher absolute premium for lower per-day decay. Position sizing on BMY should anchor to the underlying notional of $63.97 per share and to the trader's directional view on BMY stock.
BMY straddle setup
The BMY straddle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BMY at $63.97 on that close, the first option leg uses a $64.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BMY chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BMY shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $64.00 | $1.83 |
| Buy 1 | Put | $64.00 | $1.64 |
BMY straddle risk and reward
- Net Premium / Debit
- -$346.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$316.36
- Breakeven(s)
- $60.54, $67.46
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
BMY straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on BMY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$6,053.00 |
| $14.15 | -77.9% | +$4,638.70 |
| $28.30 | -55.8% | +$3,224.40 |
| $42.44 | -33.7% | +$1,810.10 |
| $56.58 | -11.5% | +$395.79 |
| $70.73 | +10.6% | +$326.51 |
| $84.87 | +32.7% | +$1,740.81 |
| $99.01 | +54.8% | +$3,155.11 |
| $113.15 | +76.9% | +$4,569.41 |
| $127.30 | +99.0% | +$5,983.71 |
When traders use straddle on BMY
Straddles on BMY are pure-volatility plays that profit from large moves in either direction; traders typically buy BMY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
BMY thesis for this straddle
The market-implied 1-standard-deviation range for BMY extends from approximately $59.43 on the downside to $68.51 on the upside. A BMY long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current BMY IV rank near 20.20% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BMY at 24.73%. As a Healthcare name, BMY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BMY-specific events.
BMY straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BMY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BMY alongside the broader basket even when BMY-specific fundamentals are unchanged. Always rebuild the position from current BMY chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on BMY?
- A straddle on BMY is the straddle strategy applied to BMY (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With BMY stock at $63.97 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed BMY chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are BMY straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the BMY straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 24.73%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$316.36 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BMY straddle?
- The breakeven for the BMY straddle priced on this page is roughly $60.54 and $67.46 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BMY market-implied 1-standard-deviation expected move in the same options snapshot is approximately 7.09%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on BMY?
- Straddles on BMY are pure-volatility plays that profit from large moves in either direction; traders typically buy BMY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current BMY implied volatility affect this straddle?
- BMY ATM IV is at 24.73% with IV rank near 20.20%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.